Loading...
Docoh
Log in Free sign up

GT Biopharma (GTBP)

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.

Company profile

Ticker
GTBP
Exchange
NASDAQ
Website
www.gtbiopharma.com
CEO
Anthony Cataldo
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
OXIS INTERNATIONAL INC
SEC CIK
0000109657
Corporate docs
IRS number
941620407

GTBP stock data

News

From Benzinga Pro
GT Biopharma Q2 EPS $(0.10) Up From $(0.15) YoY
11 Aug 22
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.
GT Biopharma Highlights Presentation Of GTB-7550 Data At EHA 2022 Congress
10 Jun 22
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivo Future studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE, Calif.,

Press releases

From Benzinga Pro
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
11 Aug 22
Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B cell malignancies at EHA 2022 Congress.GTB-5550 (B7-H3)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
19 Aug 22
31 Dec 22

Financial summary

Financial statements Chart GTBP financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.36M 5.36M 5.36M 5.36M 5.36M 5.36M
Cash burn (monthly) 642.67K 300.83K 1M 3.21M 928.67K 1.3M
Cash used (since last report) 1.08M 505.79K 1.69M 5.4M 1.56M 2.19M
Cash remaining 4.28M 4.85M 3.67M -42.09K 3.8M 3.17M
Runway (months of cash) 6.7 16.1 3.7 -0.0 4.1 2.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

GTBP insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 22 Wendel Bruce Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 50,000 124K 50,000
15 Jul 22 Wendel Bruce Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 50,000 124K 50,000
15 Jul 22 Gregory Berk Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 50,000 124K 50,000
15 Jul 22 Manu Ohri Common Stock Other Acquire J Yes No 0 100,000 0 100,000
15 Jul 22 Manu Ohri Common Stock Other Dispose J No No 0 100,000 0 0
15 Jul 22 Manu Ohri Common Stock Grant Acquire A No No 0 100,000 0 100,000
15 Jul 22 Manu Ohri Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 200,000 496K 200,000
15 Jul 22 Urban Alan Louis Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 50,000 124K 50,000
15 Jul 22 Shrotriya Rajesh C MD Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 361,476 896.46K 361,476
15 Jul 22 Shrotriya Rajesh C MD Option to purchase Common Stock Common Stock Grant Acquire A No No 2.48 50,000 124K 50,000
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

GTBP institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Sanofi • ImmunityBio • Nkarta

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: assigned, assistance, brought, chain, Comparison, confidence, conflict, consumer, cybersecurity, directly, domestic, economy, energy, environmental, exacerbate, food, fuel, gas, government, grow, higher, Incentive, inflationary, large, Oil, political, released, Russia, supply, transparency, Ukraine
Removed: attributable, notice
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q/A
2021 Q2
Quarterly report (amended)
29 Dec 21
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
23 Aug 21
NT 10-Q
Notice of late quarterly filing
17 Aug 21
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
16 Apr 21
NT 10-K
Notice of late annual filing
31 Mar 21
Current reports
View all
8-K/A
Submission of Matters to a Vote of Security Holders
17 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
8-K
Departure of Directors or Certain Officers
10 Jun 22
8-K
Departure of Directors or Certain Officers
8 Mar 22
8-K
Departure of Directors or Certain Officers
18 Feb 22
8-K
Other Events
23 Dec 21
8-K
Departure of Directors or Certain Officers
21 Dec 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Nov 21
8-K
Other Events
1 Nov 21
8-K
Other Events
23 Sep 21
Registration and prospectus
View all
S-8
Registration of securities for employees
25 Jul 22
S-1
IPO registration
22 Apr 21
POS AM
Prospectus update (post-effective amendment)
22 Apr 21
424B4
Prospectus supplement with pricing info
11 Feb 21
S-1MEF
Registration of additional securities for an S-1
10 Feb 21
S-1/A
IPO registration (amended)
9 Feb 21
8-A12B
Registration of securities on exchange
8 Feb 21
S-1/A
IPO registration (amended)
8 Feb 21
S-1/A
IPO registration (amended)
2 Feb 21
S-1
IPO registration
11 Dec 20
Proxies
View all
DEF 14A
Definitive proxy
17 Aug 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
19 Apr 22
DEF 14C
Information statement
14 Jan 21
PRE 14C
Preliminary information
30 Dec 20
DEF 14C
Information statement
11 May 17
PRER14C
Preliminary revised information
4 May 17
PRER14C
Preliminary revised information
23 Apr 17
PRER14C
Preliminary revised information
13 Apr 17
PRE 14C
Preliminary information
23 Mar 17
Other
View all
UPLOAD
Letter from SEC
25 Jan 22
CORRESP
Correspondence with SEC
28 Dec 21
UPLOAD
Letter from SEC
14 Dec 21
EFFECT
Notice of effectiveness
28 Apr 21
EFFECT
Notice of effectiveness
23 Apr 21
CORRESP
Correspondence with SEC
22 Apr 21
UPLOAD
Letter from SEC
22 Apr 21
EFFECT
Notice of effectiveness
11 Feb 21
CERT
Certification of approval for exchange listing
10 Feb 21
CORRESP
Correspondence with SEC
8 Feb 21
Ownership
View all
4
GT Biopharma / Michael Martin Breen ownership change
19 Jul 22
4
GT Biopharma / RAJESH C MD SHROTRIYA ownership change
19 Jul 22
4
GT Biopharma / ALAN LOUIS URBAN ownership change
19 Jul 22
4
GT Biopharma / Gregory Berk ownership change
19 Jul 22
4
GT Biopharma / Manu Ohri ownership change
19 Jul 22
4
GT Biopharma / Bruce Wendel ownership change
19 Jul 22
3
GT Biopharma / ALAN LOUIS URBAN ownership change
14 Jun 22
SC 13G/A
GT Biopharma / BRISTOL INVESTMENT FUND ownership change
2 Mar 22
3
GT Biopharma / Manu Ohri ownership change
18 Feb 22
4
GT Biopharma / Gavin Choy ownership change
14 Feb 22

Patents

Utility
Use and Composition for Treating Myasthenia Gravis and Other Myasthenic Syndromes
19 Feb 20
The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.
Utility
Neostigmine Combination and Compositions
1 Jan 20
The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose that attenuates or even abrogates the dose-limiting gastrointestinal adverse effects of neostigmine.
Utility
Composition of Matter and Use Thereof for Preventing and Treating Motion Sickness
4 Dec 19
Motion sickness in a mammalian subject, in particular, a human, may be prevented or treated by administering to a mammalian, a transdermal device system releasing oxybutynin or one of its enantiomers, such as (R)-oxybutynin.

Transcripts

2021 Q2
Earnings call transcript
13 Aug 21

Reddit threads

View all